组蛋白去乙酰化酶抑制剂在心血管疾病中的治疗潜力  

Therapeutic Potential of Histone Deceatylase Inhibitors in Cardiovascular Diseases

作　　者：龙殿飞 李娜 薛世珊[3] 苏国海 禹文茜 LONG Dianfei;LI Na;XUE Shishan;SU Guohai;YU Wenqian(Weifang Medical College,Weifang 261053,Shandong,China;Central Hospital Affiliated to Shandong First Medical University,Jinan 250013,Shandong,China;Jinan Central Hospital Affiliated to Shandong University,Jinan 250013,Shandong,China)

机构地区：[1]潍坊医学院,山东潍坊261053 [2]山东第一医科大学附属中心医院,山东济南250013 [3]山东大学附属济南市中心医院,山东济南250013

出　　处：《心血管病学进展》2021年第10期933-936,共4页Advances in Cardiovascular Diseases

基　　金：国家科技重大专项(2020ZX09201025);国家自然科学基金青年项目(82002987);山东省自然科学基金(ZR2018MH003);济南市临床科技创新计划(201805004)。

摘　　要：赖氨酸乙酰化是一种保守、可逆的翻译后蛋白修饰,受赖氨酸乙酰转移酶和组蛋白去乙酰化酶调控,参与多种细胞信号转导途径和疾病的发生。在动物模型中的研究揭示了可逆赖氨酸乙酰化在高血压、血管疾病、心肌梗死与缺血再灌注损伤、心肌肥厚、心力衰竭和心律失常中的调节作用。这些研究的证据表明,组蛋白去乙酰化酶抑制剂在心血管疾病中具有治疗作用。现主要描述组蛋白去乙酰化酶在心血管疾病中的不同作用,这些观察结果对组蛋白去乙酰化酶抑制剂作为心血管疾病治疗药物的临床应用具有重要意义。Lysine acetylation is a conserved,reversible,post-translational protein modification regulated by lysine acetyltransferases and histone deacetylases(HDACs)that is involved in many cellular signalling pathways and diseases.Studies in animal models have revealed a regulatory role of reversible lysine acetylation in hypertension,vascular diseases,myocardial infarction and ischemia reperfusion injury,myocardial hypertrophy,heart failure and arrhythmia.Evidence from these studies indicates a therapeutic role of HDAC inhibitors in cardiovascular diseases.In this review,we describe the diverse roles of HDACs in cardiovascular diseases.These observations have important implications for the clinical utility of HDAC inhibitors as therapeutic agents for cardiovascular diseases.

关 键 词：组蛋白去乙酰化酶 组蛋白去乙酰化酶抑制剂 心血管疾病 

分 类 号：R54[医药卫生—心血管疾病]